Evolent Health Financial Statements (EVH)
|
|
|
|
Report date
|
|
|
23.02.2024 |
10.05.2024 |
09.08.2024 |
07.11.2024 |
08.11.2024 |
|
08.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
556.1 |
639.7 |
647.1 |
621.4 |
621.4 |
|
2 530 |
|
Operating Income, bln rub |
|
|
-21.4 |
5.83 |
9.46 |
-16.3 |
-16.3 |
|
-17.3 |
|
EBITDA, bln rub |
? |
|
-6.23 |
18.8 |
40.4 |
-8.16 |
12.0 |
|
63.0 |
|
Net profit, bln rub |
? |
|
-33.4 |
-17.3 |
1.60 |
-31.2 |
-23.1 |
|
-70.1 |
|
|
OCF, bln rub |
? |
|
89.4 |
4.91 |
21.4 |
18.7 |
18.7 |
|
63.7 |
|
CAPEX, bln rub |
? |
|
6.05 |
5.35 |
7.11 |
6.29 |
6.29 |
|
25.0 |
|
FCF, bln rub |
? |
|
83.3 |
-0.438 |
14.3 |
12.4 |
12.4 |
|
38.6 |
|
Dividend payout, bln rub
|
|
|
5.16 |
5.08 |
5.07 |
5.13 |
5.13 |
|
20.4 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
317.5% |
0.00% |
0.00% |
|
-29.1% |
|
|
OPEX, bln rub |
|
|
111.0 |
68.8 |
67.2 |
97.0 |
97.0 |
|
329.9 |
|
Cost of production, bln rub |
|
|
454.4 |
565.1 |
570.5 |
540.7 |
540.7 |
|
2 217 |
|
R&D, bln rub |
|
|
6.60 |
6.30 |
6.70 |
0.000 |
0.000 |
|
13.0 |
|
Interest expenses, bln rub |
|
|
12.2 |
6.00 |
6.00 |
6.01 |
6.01 |
|
24.0 |
|
|
Assets, bln rub |
|
|
2 680 |
2 644 |
2 475 |
2 502 |
2 502 |
|
2 502 |
|
Net Assets, bln rub |
? |
|
1 068 |
1 048 |
1 054 |
1 039 |
1 039 |
|
1 039 |
|
Debt, bln rub |
|
|
644.8 |
824.4 |
819.9 |
635.2 |
635.2 |
|
635.2 |
|
Cash, bln rub |
|
|
192.8 |
216.7 |
121.3 |
112.9 |
112.9 |
|
112.9 |
|
Net debt, bln rub |
|
|
452.0 |
607.6 |
698.6 |
522.3 |
522.3 |
|
522.3 |
|
|
Ordinary share price, rub |
|
|
33.0 |
32.8 |
19.1 |
28.3 |
28.3 |
|
24.0 |
|
Number of ordinary shares, mln |
|
|
113.6 |
114.1 |
114.7 |
114.9 |
114.9 |
|
114.9 |
|
|
Market cap, bln rub |
|
|
3 752 |
3 743 |
2 193 |
3 248 |
3 248 |
|
2 753 |
|
EV, bln rub |
? |
|
4 204 |
4 350 |
2 891 |
3 771 |
3 771 |
|
3 276 |
|
Book value, bln rub |
|
|
-801 |
-800 |
-774 |
-795 |
-795 |
|
-795 |
|
|
EPS, rub |
? |
|
-0.29 |
-0.15 |
0.01 |
-0.27 |
-0.20 |
|
-0.61 |
|
FCF/share, rub |
|
|
0.73 |
0.00 |
0.12 |
0.11 |
0.11 |
|
0.34 |
|
BV/share, rub |
|
|
-7.05 |
-7.01 |
-6.75 |
-6.93 |
-6.93 |
|
-6.93 |
|
|
EBITDA margin, % |
? |
|
-1.12% |
2.94% |
6.25% |
-1.31% |
1.92% |
|
2.49% |
|
Net margin, % |
? |
|
-6.01% |
-2.70% |
0.25% |
-5.03% |
-3.72% |
|
-2.77% |
|
FCF yield, % |
? |
|
3.03% |
3.48% |
6.88% |
3.37% |
3.37% |
|
1.40% |
|
ROE, % |
? |
|
-10.6% |
-10.5% |
-7.06% |
-7.73% |
-6.95% |
|
-6.74% |
|
ROA, % |
? |
|
-4.22% |
-4.17% |
-3.01% |
-3.21% |
-2.89% |
|
-2.80% |
|
|
P/E |
? |
|
-33.2 |
-33.9 |
-29.5 |
-40.4 |
-45.0 |
|
-39.3 |
|
P/FCF |
|
|
33.0 |
28.7 |
14.5 |
29.6 |
29.6 |
|
71.3 |
|
P/S |
? |
|
1.91 |
1.72 |
0.93 |
1.32 |
1.32 |
|
1.09 |
|
P/BV |
? |
|
-4.68 |
-4.68 |
-2.83 |
-4.08 |
-4.08 |
|
-3.46 |
|
EV/EBITDA |
? |
|
1 781 |
74.3 |
40.5 |
40.0 |
58.0 |
|
52.0 |
|
Debt/EBITDA |
|
|
191.5 |
10.4 |
9.77 |
5.54 |
8.04 |
|
8.29 |
|
|
R&D/CAPEX, % |
|
|
109.1% |
117.8% |
94.3% |
0.00% |
0.00% |
|
51.9% |
|
|
CAPEX/Revenue, % |
|
|
1.09% |
0.84% |
1.10% |
1.01% |
1.01% |
|
0.99% |
|
| Evolent Health shareholders |
